Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019204 (hepatocellular carcinoma)
 71,386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Liver macrophages activated in vivo with bacterially derived lipopolysaccharide (LPS) display enhanced chemotaxis, phagocytosis, and oxidative metabolism. To determine if LPS also activates these mononuclear phagocytes for tumor cell killing, we compared the cytotoxic activity of macrophages from livers of rats treated with LPS (5 mg/kg, i.v.) with resident Kupffer cells. We found that both macrophage cell types displayed cytotoxicity towards rat N1S1 hepatoma and RBL-1 basophilic leukemia cells. Cytotoxicity of resident and LPS-activated liver macrophages towards these targets increased with cocultivation time, was dependent on the effector:target cell ratio, and appeared to involve extracellular lysis. No direct correlation between macrophage activation and cytotoxicity was observed towards these targets. While liver macrophages from LPS treated rats were more cytotoxic towards N1S1 cells, resident Kupffer cells were more cytotoxic towards RBL-1 cells. In further studies, resident Kupffer cells were also found to display extracellular cytolytic activity towards mouse P815 mastocytoma cells. In contrast, LPS-activated liver macrophage-mediated killing of these targets involved phagocytosis of intact tumor cells, as evidenced by light and electron microscopy and by uptake of 51Cr-labeled cells. These results suggest that cytotoxicity mediated by liver macrophages depends on the type of macrophage and the nature of the tumor cell target. In addition, cytotoxicity towards tumor targets appears to involve at least two different mechanisms including extracellular cytolysis and phagocytosis.
 ...
PMID:Differential sensitivity of tumor targets to liver macrophage-mediated cytotoxicity. 311 98

Antitumor effects of cyclophosphamide (CY) and lipopolysaccharide (LPS) were investigated in BCG-treated mice. C3H/He mice and CDF1 mice were injected with BCG and were inoculated subcutaneously with syngeneic mouse hepatoma and mastocytoma P815 respectively. A subsequent injection of LPS caused hemorrhagic necrosis and retarded growth of tumor. When mice were treated with LPS plus suboptimal dose of CY, tumor growth was retarded and survival time was prolonged. The antitumor effects were more remarkable when mice were treated with CY prior to the injection of LPS. Without BCG pretreatment, LPS showed no antitumor activity in mice. Sera from mice treated with BCG plus LPS was cytotoxic for cultured tumor cells. However treatment of mice with CY did not increase the in vitro cytotoxicity. In this experimental condition, CY had no effect on delayed type hypersensitivity when evaluated by the footpad reaction to purified protein derivative (PPD). These results seem to indicate that the antitumor effects of the treatment with CY and LPS in BCG-treated mice are mediated by the reduction of tumor burden by CY and a serum factor induced by LPS.
 ...
PMID:Antitumor activity of cyclophosphamide and lipopolysaccharide in tumor-bearing mice pretreated with BCG. 312 Mar 54

The cDNA for human beta 2-interferon (IFN-beta 2)/B-cell differentiation factor 2/hepatocyte-stimulating factor was expressed in Escherichia coli to yield a fusion protein which contains the 182 carboxyl-terminal amino acids of IFN-beta 2 fused to a 34-amino acid prokaryotic leader peptide (rIFN-beta 2). When added to cultures of human hepatoma cell line Hep3B2, rIFN-beta 2 as well as preparations of natural IFN-beta 2 enhance secretion of positive acute phase reactants such as alpha 1-antichymotrypsin, complement C3, fibrinogen, and alpha 1-acid glycoprotein and inhibit secretion of albumin, confirming that a protein derived from the IFN-beta 2 gene can have hepatocyte-stimulating factor activity. We have prepared a rabbit polyclonal antiserum to the E. coli-derived human IFN-beta 2 fusion protein. This polyclonal antiserum inhibits the hepatocyte-stimulating and B-cell differentiation activities of appropriate IFN-beta 2 preparations. The anti-rIFN-beta 2 antiserum has been used in immunoprecipitation experiments and in Western blots to help define the secretory proteins derived from the IFN-beta 2 gene in fibroblasts and monocytes. "Uninduced" human FS-4 fibroblasts as well as those induced with interleukin-1 alpha, tumor necrosis factor, or bacterial lipopolysaccharide secrete at least five forms of IFN-beta 2 of apparent molecular mass in the range from 23 to 30 kDa which can be resolved by polyacrylamide gel electrophoresis under denaturing and reducing conditions. The three higher molecular mass forms are not observed when FS-4 cells are induced in the presence of tunicamycin, suggesting that these forms are N-glycosylated (gp28, gp29, and gp30). Although secretion of the two lower molecular mass forms is resistant to tunicamycin, they are labeled by [3H]glucosamine (gp23-gp25). The inclusion of cycloheximide during the [35S]methionine labeling of induced FS-4 cells results in the preferential synthesis and secretion of the 29-kDa triplet. Human monocytes induced with bacterial lipopolysaccharide also secrete several distinct forms of IFN-beta 2 in the size range from 23 to 30 kDa which co-migrate in polyacrylamide gels with those obtained from FS-4 cells. Our observations help relate previous descriptions of multiple forms of hepatocyte-stimulating factor to specific proteins derived from the IFN-beta 2 gene.
 ...
PMID:Synthesis and secretion of multiple forms of beta 2-interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes. 313 26

The rat hepatoma cell line MH1C1 has been characterized to show a stimulated secretion of C-reactive protein in response to both leukocyte supernatant and a purified human interleukin-1 preparation. The time-dependency and dose-response relationship of CRP secretion were comparable to and somewhat more sensitive than the effects of leukocyte supernatant and purified human interleukin-1 on the proliferative rate of murine thymocytes; the proliferative rate of the hepatoma cell line MH1C1 was unchanged under these conditions. Agents which affect the thymocyte bioassay response to interleukin-1 namely interleukin-2, lipopolysaccharide, concanavalin A and phytohemagglutinin showed no effect on the C-reactive protein release of the MH1C1 cell line. These data strongly support the suitability of this cell line for the in vitro study of the hepatic acute phase stimulus-secretion response.
 ...
PMID:The use of the rat hepatoma cell line MH1C1 to investigate the stimulus-secretion response of hepatic acute phase proteins. 326 28

Human C-Reactive protein (CRP) is inducible in liver cells during acute inflammation. Around 90 bp from the 5' flanking region of the human CRP gene contain, as shown here, information to induce the expression of a linked bacterial CAT gene specifically in human hepatoma (Hep3B) cells. The promoter is induced rapidly, faithfully and at high efficiency when transfected cells are exposed to conditioned medium from lipopolysaccharide stimulated peripheral monocytes. The sequences required for inducibility are located immediately upstream to the TATA element. A DNA segment from base -121 to -50 is capable of inducing transcription from the heterologous SV40 early promoter. Induction of CRP expression is probably exerted via the binding of at least one positive trans-acting factor.
 ...
PMID:Identification of sequences responsible for acute-phase induction of human C-reactive protein. 337 54

The biological activities of synthetic glycolipids, which were chemically synthesized and based on the structure of lipid A of the lipopolysaccharide (LPS) from Escherichia coli, were examined with special reference to their adjuvant activity on the induction of delayed-type hypersensitivity, activity on the induction of tumour necrotic factor (TNF) and tumour regressive activity on line 10 hepatoma in strain 2 guinea pigs. Among them, a compound structurally corresponding to free E. coli lipid A (compound 506) as well as LPS exhibited potent adjuvant activity in the induction of delayed-type hypersensitivity in guinea pigs and TNF inducing activity in the sera of mice which were presensitized with Propionibacterium acnes. Compound 506 showed potent lethal toxicity in the intravenous administration of BALB/c mice presensitized with P. acnes. The regressive activity on line 10 hepatoma was observed by the multiple intralesional injection of squalane-treated compounds 504 and 505 in strain 2 guinea pigs.
 ...
PMID:Adjuvant and antitumour activities of synthetic lipid A analogues. 396 49

Interleukin-1 (IL-1) production by monocytes of patients with various forms of malignant disease was measured after activating the cells with either lipopolysaccharide or malignant K562 cells. Monocytes from all the patients with large tumour masses, including 10 patients with hepatocellular carcinoma, produced considerably less IL-1 than controls or patients with small tumour burdens. After treating control or patient monocytes with human leucocyte interferon for 1 h prior to activation, IL-1 production was markedly improved. Depressed IL-1 production is, therefore, a further aberration in mononuclear function observed in patients with cancer.
 ...
PMID:Defective interleukin-1 production by monocytes from patients with malignant disease. Interferon increases IL-1 production. 660 4

The local antitumor activities and inflammation-inducing activities of various antitumor polysaccharides were examined and the relation between the two types of activity was studied. The tested antitumor polysaccharides included MG (a mannoglucan prepared from the culture fluid of Microellobosporia grisea), lentinan, bacterial lipopolysaccharide, TAK (a glucan from Alcaligenes faecalis) and their derivatives. Local antitumor activity was tested by intratumoral administration of the polysaccharides 4, 7 and 10 days after inoculation of MH134 hepatoma intradermally (id) into the abdomen of C3H/He mice. MG and its derivatives showed strong local antitumor activity. Inflammation-inducing activity was assayed by measuring foot-pad swelling and accumulation of iv-injected 51Cr-labeled spleen cells after injection of the test materials into the footpads of C3H/He mice. TAK had the strongest inflammation-inducing activity among the polysaccharides tested. No close correlation was found between the local antitumor activity and the inflammation-inducing activity.
 ...
PMID:Different local therapeutic effects of various polysaccharides on MH134 hepatoma in mice and its relation to inflammation induced by the polysaccharides. 674 66

Lentinan inhibited the proliferation of MH-134 ascites hepatoma transplanted subcutaneously. The best result occurred when 1 mg-2 mg/kg of lentinan was administered for 10 consecutive days from the eighth day after tumor transplantation. Tumor proliferation was 33% inhibited as measured by the average tumor diameter. The average survival (days) when chemotherapy with mitomycin-C (MMC), 5-FU and Ara-C in combination with lentinan, was administered concurrently in the second week of the tumor transplantation was 29.2 days as compared to 20.5 days in the untreated group, 25.1 days in the group given lentinan alone, and 22.0 days in the group receiving chemotherapy alone. When lentinan was administered in combination with bacterial lipopolysaccharide (LPS), the group given lentinan for 5 consecutive days from the third day after tumor transplantation and 30 micrograms LPS i.p. on the thirteenth day, had 70% inhibition of tumor as measured by the average tumor weight. The antitumor activity of lentinan was studied by following changes in macrophage migration inhibition activity (MI). In the untreated group, MI activity disappeared on the 14th day after tumor transplantation. In the group treated with lentinan, spleen cells had positive activity suggesting a restorative action of lentinan on the immune suppression accompanying tumor growth.
 ...
PMID:Antitumor effect of polysaccharide lentinan on MH-134 ascites hepatoma in C3H/He mice. 706 33

A combination of lentinan and bacterial lipopolysaccharide (LPS), previously reported to have strong antitumor activity against some tumors, was only slightly effective on solid-type MH134 hepatoma and colon 38 adenocarcinoma and was not effective on ascitic L1210 in CDF1 mice. On the other hand, additional combination therapy with cyclophosphamide (CY), that is, lentinan plus LPS plus CY, strongly inhibited the growth of solid-type MH134 and colon 38 adenocarcinoma even when administered from day 12 after tumor inoculation. The antitumor delayed hypersensitivity reaction against MH134 hepatoma, measured by means of the footpad test, was augmented by this combination. The possible role of CY is discussed in relation to the importance of inhibition of immune suppressive mechanisms in this combination therapy.
 ...
PMID:Combination therapy of murine tumors with lentinan plus lipopolysaccharide plus cyclophosphamide. 716 May 85


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>